CELTIC PHARMA AND NEUROBIOLOGICAL TECHNOLOGIES START XERECEPT TRIAL

Celtic Pharmaceutical and Neurobiological Technologies have announced the enrollment of the first patient into the second of two Phase III pivotal trials of Xerecept, corticotropin-releasing factor, for the indication of peritumoral brain edema.

This study, termed the Acute Trial, will compare the treatment of dexamethasone with Xerecept in patients already on low dose steroid whose dose must be escalated to treat their symptoms. Once patients complete the study, they have the option of entering a third, open-label, study allowing them to continue receiving Xerecept.